Unlabelled: Fasciitis with eosinophilia (FE) is a rare connective tissue disease. Due to its rarity, large-scale studies are lacking, which makes its treatment challenging. Systemic corticosteroids (SCSs) are the cornerstone of treatment; however, additional immunosuppressive drugs (ISDs) are frequently necessary (usually methotrexate). We report 2 patients, for whom an SCS and methotrexate were not a viable long-term option. In the first case, we were unable to taper the SCS dose without symptom relapse, the patient showed only a partial response to methotrexate and presented side effects. The second case never fully responded to the SCS and methotrexate and demonstrated serious SCS adverse effects. Both patients were started on tocilizumab with extremely favourable results, making this drug a potential therapeutic weapon for these patients.
Learning Points: The treatment of FE is challenging and mainly based on retrospective reviews, open-label trials and case reports, all of which included a small number of patients.Currently, systemic corticosteroids are the mainstay of treatment; however, other ISDs are frequently necessary.Cases showing a favourable clinical response to tocilizumab have recently been described in patients with corticosteroid-refractory disease, suggesting that this drug may potentially become a therapeutic weapon for these patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162578 | PMC |
| http://dx.doi.org/10.12890/2020_001485 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events.
J Immunother Cancer
October 2024
Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah University Medical Center Division of Internal Medicine, Jerusalem, Israel.
Article Synopsis
- Immune checkpoint inhibitors (ICI) for cancer like pembrolizumab and nivolumab can lead to immune-related adverse events (Eo-irAE), including high eosinophil levels that may predict positive treatment responses but can also cause significant organ dysfunction.
- This study evaluates the use of interleukin (IL) 5-axis inhibition to treat Eo-irAE, using medications like mepolizumab and benralizumab in three patients who developed these adverse effects after ICI therapy.
- Results showed rapid improvement in symptoms and a reduction in eosinophil levels with no negative impacts from the IL-5 targeted treatments, indicating they can be effective in managing Eo-irAE in cancer patients undergoing ICI
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome with Multiple Drugs (Leflunomide and Cefuroxime): A Case Report.
Curr Drug Saf
September 2024
Department of Pharmacognosy, Goa College of Pharmacy, Government of Goa, Panaji, Goa.
Article Synopsis
- Adverse Drug Reactions (ADRs) can occur even when medications are taken correctly, with DRESS syndrome being a severe type that affects multiple organ systems and requires quick diagnosis and withdrawal of the offending drug to improve outcomes.
- A case study of a 42-year-old woman highlights DRESS syndrome development after taking leflunomide, leading to serious symptoms including fever, skin rash, and liver injury, confirmed as a "definite" ADR.
- The study emphasizes that both leflunomide and cefuroxime can trigger DRESS syndrome, underscoring the need for careful monitoring of these medications and proper reporting of adverse reactions.
Eosinophilic Fasciitis: A Classic Presentation.
Mayo Clin Proc
October 2024
Department of Dermatology, Mayo Clinic, Jacksonville, FL. Electronic address:
Eosinophilia-myalgia syndrome presenting with overlapping features of eosinophilic fasciitis and sarcoidal granulomas.
JAAD Case Rep
August 2024
Department of Dermatology, University of Utah, Salt Lake City, Utah.
Unmasking the Veiled Intruder: A Complicated Case of Eosinophilic Fasciitis.
Cureus
July 2024
Rheumatology, Allergy, and Immunology, Stony Brook University, Stony Brook, USA.
Article Synopsis
- - Eosinophilic fasciitis (EF) is a rare disease that causes skin and fascia to thicken, but it doesn’t affect internal organs or have specific autoantibodies, with the presence of eosinophils in blood being a key feature
- - Patients with EF may experience symptoms like joint pain and contractures because of tissue fibrosis
- - A case study highlights a patient with skin thickening in her limbs, diagnosed through a skin biopsy, emphasizing the need to identify EF's specific clinical and microscopic traits
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!